PMV Pharmaceuticals, Inc. (PMVP)

1,6900 -0,1150 (-6,37%) Al cierre: 04:00PM EDT

PMV Pharmaceuticals, Inc.

1 Research Way
Princeton, NJ 08540
United States
609 642 6670
https://www.pmvpharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 63

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. David H. Mack Ph.D.	Co-Founder, CEO, President & Director	762,02k	N/A	1962
Dr. Arnold J. Levine Ph.D.	Co-Founder, Director & Member of Scientific Advisory Board	140k	N/A	1940
Dr. Thomas E. Shenk Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1947
Mr. Michael Carulli	Chief Financial Officer	N/A	N/A	N/A
Mr. Robert Ticktin	General Counsel, Head of Operations & Company Secretary	N/A	N/A	1962
Mr. Tim Smith	Senior VP & Head of Corporate Development and Investor Relations	N/A	N/A	N/A
Ms. Crystal Zuckerman	Vice President of Human Resources	N/A	N/A	N/A
Dr. Binh Vu Ph.D.	Senior VP of Drug Discovery & CMC	N/A	N/A	N/A
Dr. Deepika Jalota Pharm.D.	Chief Development Officer	579,96k	87,59k	1977
Dr. Marc Fellous M.D.	Senior VP and Head of Clinical Development & Medical Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de PMV Pharmaceuticals, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 6; Tablero: 6; Derechos de los accionistas: 7; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.